Background: Analysis of estrogen receptor (ER), progesterone receptor (PgR) and HER2 status in early breast cancer (EBC) is increasingly being conducted in core needle biopsies (CNBs) taken at diagnosis but the concordance with the excisional biopsy (EB) is poorly documented.
introduction
Breast cancer is the most frequently diagnosed neoplasm among women in the United States and Western countries and is the second leading cause of cancer death among women [1] . Although it continues to be an important cause of cancer morbidity and mortality, the death rates have drastically decreased due to earlier detection and more effective treatment. Over recent years, the role of core needle biopsy (CNB) has become well established as an important diagnostic tool for both palpable and nonpalpable breast lesions and it is considered the method of choice for tissue sampling as part of the triple assessment of breast disease [2, 3] . The accuracy of the CNB for the diagnosis of breast carcinoma has been extensively studied and good concordance rate has been reported between CNB and excisional biopsy (EB) for diagnosis of breast carcinoma (91%-100%) with a specificity rate ranging from 96% to 100% [4, 5] .
In addition to the histopathological diagnosis, there is a growing demand for prognostic information and in particular the determination of estrogen receptor (ER), progesterone receptor (PgR) and HER2 for treatment planning. In situations where neoadjuvant therapy is used, such information is often needed for selection of therapy and maybe the only tissue available for consideration of postsurgical care, e.g. in cases achieving a pathological complete response with treatment. Even in the presence of residual disease, there is also the concern of changes in the tumour profile due to treatment effect [6] The status of ER, PgR and HER2 is critical in the management of patients with invasive breast carcinoma [7] . ER is a powerful predictive factor for response to endocrine treatment and long-term outcome. Similarly, HER2 overexpression has been associated with worse prognosis in patients with newly diagnosed breast carcinoma, is a determinant of response to trastuzumab and a possible marker of resistance to certain endocrine and chemotherapy treatments [8] [9] [10] .
Due to the possible heterogeneous distribution of the antigens within the tumour, CNB may not accurately reflect the histological features and biological profile of the tumour. Previous studies have concluded that CNB can be used to assess hormone receptor (HR) and HER2 status. However, most of the studies included only a small number of samples with a limited statistical power to detect discordance, and results differed significantly between them [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] (Table 1) . Results from different studies differ considerably with concordance rates ranging from 61% to 99%, 61% to 91% and 64% to 96% for ER, PgR and HER2, respectively. In the case of HER2 determination, for which there are fewer studies, a wide variability in HER2 positivity has been observed between studies (7%-26%).
The purpose of this study was to compare the ER, PgR and HER2 status, including immunohistochemistry (IHC) and FISH analyses in the core biopsy with those obtained in the subsequent EB for patients diagnosed with early breast cancer (EBC) to determine level of concordance between CNB and EB in our institution.
patients and methods

patients and samples
We retrospectively collected data from our records from patients with EBC presenting to The Royal Marsden Hospital from June 2005 to September 2007 who had CNB and subsequent surgical EB or who had their pathology reviewed in our institution. CNB and EB specimens were fixed in neutralbuffered saline and embedded in paraffin before histopathological analysis. Patients who received neoadjuvant (primary) systemic treatment were excluded to avoid any changes on tumour marker determination due to the effect of the treatment. Patients with more than one tumour were included only if both CNB and EB were available for each tumour.
ER, PgR and HER2 determination
ER and PgR were determined by IHC using the SP1 antibody (Ventana) and the IE2 antibody (Ventana), respectively. Nuclear staining graded from 0 to 8 using the Allred score [24] . Scores of >2 were considered positive. HER2 was determined by IHC and was scored from 0 to 3+. Scoring of 2+ was assigned when there was weak to moderated complete membrane staining in >10% tumour cells; whereas scoring 3+ consisted of uniform, intense membrane staining of >10% of invasive tumour cells. 
statistical analysis
Sensitivity, specificity and the negative and positive predictive values were calculated by considering CNB the test assessment and EB the gold standard. Exact 95% confidence intervals (CIs) were calculated based on the binomial distribution.
results
A total of 336 samples from 332 patients were included. Two patients were diagnosed with two tumours and another one with three different areas of breast disease. CNB and EB were mostly carried out at the Royal Marsden Hospital (85% and 95% respectively) and other results were based on histological blocks sent for staining from outside institutions. Surgery carried out was mainly breast conserving (70% cases) with almost 30% of the patients undergoing a mastectomy ( Table 2 ). The median time between CNB and EB was 27 days. Most of the tumours were invasive ductal carcinoma both in the CNB and EB (82% and 81%, respectively). Although comparison of grade was not the focus of this report, it was notable that a higher proportion of tumours was diagnosed as grade 3 in EB compared with CNB (43.5 versus 28.3%, respectively; P < 0.001).
ER was scored as positive in 253 (75%) of the CNB and negative in 83 (25%). In the EB, ER was positive in 255 (76%) of the cases and negative in 79 (24%) ( Table 3 ). There was concordance between the ER assessment of CNB and EB in 330 Table 4 . In four of the six discrepancies, Allred scoring was negative in the CNB and was reported as positive in final EB. In all but one of the discrepant cases the positive score was borderline or only modestly positive. For PgR in the CNB, 66% were scored as positive compared with 67.6% in the surgical specimen. The concordance rate for PgR was 85%. The 52 discrepant cases were almost equally divided in CNB+/EB2 and CNB2/EB+ (23 and 29, respectively); 15 of the 52 (29%) implied a change in tumour HR status. In six the status changed from HR positive (ER2, PgR+) to negative. Five samples were scored as PgR 0/8 in the EB being previously scored in the initial CNB as 3/8 and 4/8 in two cases each, and 5/8 in the remaining one. One sample that was scored as 4/8 in the CNB was later scored as 2/8 in the final EB. In the nine cases where the status changed from HR2 (ER2 and PgR2) in the CNB to HR+ (PgR+) in the EB, all were initially scored as 0/8 and then changed to 3/8 in two cases, 4/8 in three, 5/8 in three and 7/8 in one.
Median score for ER and PgR compared between CNB and EB was the same: 8 in both for ER and 5 in both for PgR. Similarly, mean values for these markers were 5.9 versus 5.8 for ER and 4.4 versus 4.4 for PgR for CNB and EB, respectively. HER2 was not assessed in five CNBs due to the lack of sample. From the 331 remaining, 41 (12.4%) patients were HER2 positive in the core and 286 (86.4%) were negative. The remaining four (1.2%) cases were assessed as HER2 2+ with no FISH being able to be carried out. Of these four, all but one was reported as HER22in the EB. A total of 44 patients were HER2+ in the EB (13.3%) and the remaining 287 (86.7%) were negative. We found only four discrepancies with a concordance of 98.8 % (Table 5 ). In all these four discrepant cases, the level of amplification for the positive case was between 2.0 and 3.0 showing only low level of amplification.
Rates for sensitivity, specificity, negative predictive value and positive predictive value using the EB as reference for each marker are summarised in Table 6 . discussion CNB is widely used in routine preoperative practice as part of the triple assessment in patients with suspected breast carcinoma. It is a reliable method for histopathological diagnosis and offers the advantage over fine needle aspiration of providing enough material to perform IHC determination for the evaluation of additional markers in EBC [2, 3] . However, there may be a concern that CNB may be less reliable than EB due to the smaller sample size, sampling error on an heterogeneous tumour and/or crash or edge artefacts in the CNB. This has major clinical implications since the expression of markers such as ER, PgR and HER2 will guide therapeutical planning [7] and, in some cases (e.g. before primary systemic treatment), the results obtained from the core biopsy are the only data available before primary systemic treatment.
Overall, previous publications suggest that the concordance rate between CNB and EB is higher for ER than for PgR. A tendency for upscoring in CNB compared with EB has also been described. This finding has been attributed to better fixation in the core biopsy samples compared with the surgical specimen.
For HER2 determination, results have been described as showing a good concordance rate. However, robust interpretation is limited by the small number of cases reviewed and the inconsistent assessment of HER2 in some studies. The American Society of Clinical Oncology (ASCO)/College of American Pathologists guidelines [25] for HER2 determination highlight that CNBs with edge or retraction artefact involving the entire core or crush artefact should not be used as a sample All six samples were internal reviews carried out at the Royal Marsden Hospital. ER, estrogen receptor; CNB, core needle biopsy; EB, excisional biopsy. original article Annals of Oncology to perform or interpret a HER2 IHC assay. These artefacts were not found to be significant features in this series. To our knowledge, our results are the largest published series of samples testing ER, PgR and HER2 in the same group of patients. We used antibodies, methodology and scoring that are in widespread use. We have found, as previously described, a good correlation for ER (98.2%) with sensitivity of 98.4% and specificity of 97.5%. We have not identified a tendency of a higher ER in CNB as previously described by other groups. For PgR, the correlation between CNB and EB is similar to previous data (85%), but we consider that the discordance rate is significant enough that the results obtained in CNB should be used cautiously. Reasons to explain this discrepancy for PgR are the fact that PgR tends to be distributed more heterogeneously within the tumour [26] . Greater levels of discrepancy for PgR than for ER and HER2 have also been described between the small samples placed in tissue microarrays compared with whole section [27] .
Previous studies have reported concordance between core and surgical specimen for HER2 of 90%. In this study, our correlation rate was 98.8%. One explanation for our high correlation rate is that we carried out FISH testing in all HER2 2+ cases in which tumour sample was available and in all discrepancies between CNB and EB. Since the completion of the analysis on our series, updated ASCO guidelines on HER2 diagnosis have been published [25] . Following these guidelines, the definition of HER2 positivity has been altered slightly. IHC has to be scored as 3+ (intense complete staining of the membrane >30% of cancer cells) or FISH ratio needs to be >2.2. It is also recommended that to perform HER2 testing, laboratories must have at least a 95% concordance with another validated test for positive and negative assay values for a correct evaluation of HER2. If we follow the ASCO recommendations, one of our discordant cases would not be defined as a discrepancy given a FISH ratio of 2.08 (Table 5) .
More important than the discordance rates observed are the clinical implications of these discrepancies. The Allred scoring system used for ER and PgR is based on a combination of proportion of positive cells staining and the intensity of positive staining with a score of >2 considered positive [24] . With this scoring system, a tumour sample with a single strongly intensive staining cell would be reported as score 4/8, and therefore positive, yet this same tumour might be readily be scored negative in another sample. The degree of absolute difference in scores was small in some cases. In two of the discrepancies where ER was positive in CNB and converted to negative in EB, the scoring changed from 3/8 to 2/8 and 0/8. In two of the cases where ER was scored negative in CNB but positive in EB, change in score was from 0/8 to 4/8 ( Table 4) . There is information available suggesting a relationship between quantitative ER and PgR levels and outcome on endocrine treatment [28] [29] [30] , thus where discrepancies are small, the denial of therapy would be likely to be of modest importance.
PgR is infrequently expressed in ER2 tumours and is usually considered less important than ER. However, those cases in which a discrepancy in its determination leads to a change in HR status would be of substantial importance since it would imply a change in treatment. It is also notable that a PgR2 status is related to worsening prognosis and this could have implications in clinical management of the patient and treatment decisions, e.g. in deciding whether to administer chemotherapy in addition to endocrine treatment. In our series, change in HR status related to discordance of PgR occurred in 15 paired samples (4.5%). Though this is not as high as the overall 15% of PgR discrepancies found, we consider that it is high enough for PgR results in CNBs to be considered carefully.
In conclusion, our study, the largest published to date to determine correlation rate for ER, PgR and HER2 between CNB and EB, indicates that ER and HER2 status can be accurately assessed in CNB. The 15% discordance rate observed for PgR indicates that PgR status in CNBs should be interpreted cautiously. 
